COVID-19 Vaccination-Related Delayed Adverse Events among Patients with Systemic Lupus Erythematosus
Issued Date
2023-12-01
Resource Type
eISSN
20770383
Scopus ID
2-s2.0-85180664309
Journal Title
Journal of Clinical Medicine
Volume
12
Issue
24
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Clinical Medicine Vol.12 No.24 (2023)
Suggested Citation
Dey M., Doskaliuk B., Lindblom J., Nikiphorou E., Wincup C., Fathima M., Saha S., Shaharir S.S., Katchamart W., Goo P.A., Traboco L., Chen Y.M., Kadam E., Lilleker J.B., Nune A., Pauling J.D., Agarwal V., Dey D., Toro Gutierrez C.E., Caballero C.V., Chinoy H., Aggarwal R., Agarwal V., Gupta L., Parodis I. COVID-19 Vaccination-Related Delayed Adverse Events among Patients with Systemic Lupus Erythematosus. Journal of Clinical Medicine Vol.12 No.24 (2023). doi:10.3390/jcm12247542 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/95517
Title
COVID-19 Vaccination-Related Delayed Adverse Events among Patients with Systemic Lupus Erythematosus
Author's Affiliation
Faculty of Medicine and Health
Siriraj Hospital
Faculty of Biology, Medicine and Health
Bristol Medical School
Southport and Ormskirk Hospital NHS Trust
Pontificia Universidad Javeriana, Cali
Seth GS Medical College and KEM Hospital
Universidad del Norte
North Bristol NHS Trust
Ivano-Frankivsk National Medical University
Sanjay Gandhi Postgraduate Institute of Medical Sciences
Mymensingh Medical College
King's College Hospital
Karolinska Universitetssjukhuset
University of Ghana
King's College London
Salford Royal NHS Foundation Trust
Birmingham City Hospital
The Royal Wolverhampton NHS Trust
Veterans General Hospital-Taichung Taiwan
Salford Royal Hospital
University of Pittsburgh School of Medicine
Faculty of Medicine, UKM
St. Luke’s Medical Center-Global City
Mahatma Gandhi Mission Medical College
Queen Savang Vadhana Memorial Hospital
Siriraj Hospital
Faculty of Biology, Medicine and Health
Bristol Medical School
Southport and Ormskirk Hospital NHS Trust
Pontificia Universidad Javeriana, Cali
Seth GS Medical College and KEM Hospital
Universidad del Norte
North Bristol NHS Trust
Ivano-Frankivsk National Medical University
Sanjay Gandhi Postgraduate Institute of Medical Sciences
Mymensingh Medical College
King's College Hospital
Karolinska Universitetssjukhuset
University of Ghana
King's College London
Salford Royal NHS Foundation Trust
Birmingham City Hospital
The Royal Wolverhampton NHS Trust
Veterans General Hospital-Taichung Taiwan
Salford Royal Hospital
University of Pittsburgh School of Medicine
Faculty of Medicine, UKM
St. Luke’s Medical Center-Global City
Mahatma Gandhi Mission Medical College
Queen Savang Vadhana Memorial Hospital
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: The safety profile of COVID-19 vaccination is well documented, but hesitancy among people with immune-mediated inflammatory diseases, often immunocompromised, remains high, partially due to a scarcity of data on safety over a longer term. We herein aimed to assess delayed adverse events (DAEs) occurring >7 days after COVID-19 vaccination in systemic lupus erythematosus (SLE) versus other rheumatic autoimmune diseases (rAIDs), non-rheumatic AIDs (nrAIDs), and healthy controls (HCs). Methods: Self-reported data were captured within the COVID-19 Vaccination in Autoimmune Diseases (COVAD)-2 online survey, which comprised >150 centres and responses from 106 countries, between February and June 2022. Logistic regression analysis adjusting for important confounders (age, sex, ethnicity) was used to compare groups. Results: Of 7203 eligible individuals, 882 (12.2%) patients had SLE, 3161 (43.9%) patients had rAIDs, 426 (5.9%) patients had nrAIDs, and 2734 (38.0%) were HCs. SLE patients had a median age of 39 years (IQR: 31–50); 93.7% were women. SLE patients reported, more frequently, major DAEs (OR: 1.6; 95% CI: 1.2–2.0; p = 0.001) and hospitalisation (OR: 2.2; 95% CI: 1.4–3.4; p < 0.001) compared to HCs, severe rashes (OR: 2.4; 95% CI: 1.3–4.2; p = 0.004) compared to people with rAIDS, and hospitalisation (OR: 2.3; 95% CI: 1.1–4.9; p = 0.029) as well as several minor DAEs compared to people with nrAIDs. Differences were observed between vaccines in terms of frequency of major DAEs and hospitalisations, with the latter seen more frequently in patients receiving the Moderna vaccine. People with SLE with no autoimmune multimorbidity less frequently reported overall minor DAEs compared to SLE patients with comorbid nrAIDs (OR: 0.5; 95% CI: 0.3–1.0; p = 0.036). Conclusion: Hospitalisations post-vaccination were more frequent in SLE patients than in HCs. Monitoring of SLE patients following COVID-19 vaccination can help in identifying DAEs early, informing patients about expected DAEs, and supporting patients, especially those with autoimmune multimorbidity.